-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
As-358
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2222042-47-7.gif)
| Category | Virus Protease |
| CAS | 2222042-47-7 |
| Description | As-358 has inhibitory effects against Ebola virus and Marburg virus, with IC50s of 47.5 μM and 3.7 μM. |
Product Information
| Synonyms | As-358|CHEMBL4278533|HY-146883|CS-0438998 |
| Molecular Weight | 93.44 |
| Molecular Formula | C18H31NO2 |
| Canonical SMILES | CC1(C2CCC1(C(C2)OC(=O)CCN3CCCCC3)C)C |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 400 |
| Exact Mass | 293.235479232 |
| In Vitro | As-358 has inhibitory activity against EBOV and MALV. As-358(0-100 μM; 48 hours) can inhibit WT-EboV GP and mutant D522A-EboV GP, IC50s 1.7 and 2.2 μM respectively. |
| Target | IC50: 47.5 μM (EBOV), 3.7 μM (MARV) |
| XLogP3-AA | 3.9 |
